Hybio Pharmaceutical (300199) Fundamentals 2026 — P/E 205.3x, Revenue Analysis | SniperIQ
Hybio Pharmaceutical (300199) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥19.0B, trading at ¥21.47 on the SHZ. This SniperIQ fundamentals page covers Hybio Pharmaceutical's valuation (P/E 205.3x, P/B 26.4x), profitability (net margin 9.9%), revenue (¥966M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hybio Pharmaceutical's market cap?
Hybio Pharmaceutical (300199) has a market capitalization of approximately ¥19.0B, trading at ¥21.47 on the SHZ. Market cap moves with the live share price.
What is Hybio Pharmaceutical's P/E ratio?
Hybio Pharmaceutical's trailing twelve-month P/E ratio is 205.3x, with a price-to-book (P/B) of 26.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hybio Pharmaceutical?
Hybio Pharmaceutical runs a net profit margin of 9.9%, a gross margin of 59.9%, and an operating margin of 16.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hybio Pharmaceutical generate?
Hybio Pharmaceutical reported revenue of ¥966M for fiscal year 2025, with net income of ¥37M and earnings per share (EPS) of 0.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hybio Pharmaceutical pay a dividend?
Hybio Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Hybio Pharmaceutical financially healthy?
Hybio Pharmaceutical carries a debt-to-equity ratio of 2.43x and a current ratio of 0.43x, with a market beta of 0.72. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hybio Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hybio Pharmaceutical (300199) the key facts are: market cap ¥19.0B, P/E 205.3x, revenue ¥966M, 52-week range 16.23-31.19. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hybio Pharmaceutical's full fundamentals live
Get Hybio Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.